Bio-pharmaceuticals

Chengdu is a national-level biomedical research, development and innovation industrial base. It is one of China’s first batch of drug export bases, a national high-tech biomedical material and device industrialization base, a national (Chengdu) biomedical innovation and incubation base, a major new drug innovation base, and a major national scientific and technological achievements transfer and demonstration pilot base.

Chengdu has essentially established the whole industry chain, from new drug screening and safety evaluation to clinical research and production, as well as a business ecosystem favorable for the development of the biomedical industry.

Adhering to a development pathway that is "innovation-driven and integrates medicine, medication and health care with high-end positioning and a forward-looking layout", Chengdu has been making efforts to create a favorable industrial environment, deepening international cooperation and technical exchanges. The cluster of Tianfu International Biotown in High-tech Zone, Chengdu Medical City in Wenjiang District and Tianfu Traditional Chinese Medicine City has formed a coordinated development area.

In recent years, based on local companies such as Kelun, Kanghong Pharmaceutical, Brilliant Pharmaceutical Group, DIAO Group, Enwei Group, Chengdu Institute of Biological Products, ROSEN and Easton Biopharmaceuticals, well-known enterprises at home and abroad have settled in Chengdu, including Medtronic, Sanofi, Allergan, Hengrui Medicine, Mindray Medical, Yangtze River Pharmaceutical and Chipscreen Biosciences. In 2018, Chengdu's main business income from the biopharmaceutical industry reached 59.6 billion yuan ($8.55 billion), with a rapid growth rate of 21.6 percent.